GlassScriptPhysician profile
Matthew Ryan Hunsucker
NPI 1285012625
$9,430.96
in general payments reported to CMS, 2019-2025
30 companies · $4,829 in 2025
The $4,829 reported for 2025 was more than what 88% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $1,106 · 2023: $1,714 · 2024: $1,361 · 2025: $4,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,429 · Consulting Fee: $2,500 · Travel and Lodging: $926 · Education: $49.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,428.65 |
| Consulting Fee | $2,500.00 |
| Travel and Lodging | $925.79 |
| Education | $49.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $3,522.41 | 2025 | |
| United Therapeutics Corporation | $810.90 | 2021-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $807.02 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $665.35 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.23 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $374.13 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $273.61 | 2022-2025 | Dupixent |
| Mylan Specialty L.P. | $263.50 | 2022-2024 | Yupelri |
| Amgen INC. | $251.94 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $243.68 | 2022-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $237.08 | 2022-2025 | Zerbaxa, Winrevair, Dificid |
| Grifols USA, LLC | $234.57 | 2022-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $182.63 | 2025 | Ohtuvayre |
| Baxter Healthcare | $135.10 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $126.72 | 2021-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $121.55 | 2022-2025 | Smartvest |
| Insmed, INC. | $111.70 | 2024-2025 | Brinsupri, Arikayce |
| Davol INC. | $105.54 | 2023 | Phasix Mesh |
| Breas Medical, INC. | $61.47 | 2024 | Vivo 45 Ls |
| Takeda Pharmaceuticals U.S.A., INC. | $58.06 | 2023-2024 | Glassia |
| Teva Pharmaceuticals USA, INC. | $54.58 | 2021-2023 | |
| Shionogi INC | $51.81 | 2022-2024 | Fetroja |
| Novartis Pharmaceuticals Corporation | $50.12 | 2024-2025 | |
| Viatris Specialty LLC | $34.90 | 2025 | Yupelri |
| Genentech USA, INC. | $32.47 | 2021-2023 | Xolair |
| Pfizer INC. | $32.39 | 2024 | |
| Harmony Biosciences LLC | $21.48 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $17.06 | 2025 | Lumryz |
| Mallinckrodt Hospital Products INC. | $17.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hunsucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.